{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T04:14:54Z","timestamp":1747282494652,"version":"3.40.5"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Crosswise tasks of Soochow University","award":["P112210923"],"award-info":[{"award-number":["P112210923"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-11007-0","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T20:20:46Z","timestamp":1747254046000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and safety of azvudine versus nirmatrelvir\/ritonavir in hospitalized patients with COVID-19"],"prefix":"10.1186","volume":"25","author":[{"given":"Jin","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiao","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-feng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"issue":"1","key":"11007_CR1","doi-asserted-by":"publisher","first-page":"e2373","DOI":"10.1002\/rmv.2373","volume":"33","author":"SJRD Silva","year":"2023","unstructured":"Silva SJRD, Kohl A, Pena L, Pardee K. Recent insights into SARS-CoV-2 Omicron variant. Rev Med Virol. 2023;33(1):e2373.","journal-title":"Rev Med Virol"},{"issue":"6","key":"11007_CR2","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/s41573-023-00672-y","volume":"22","author":"G Li","year":"2023","unstructured":"Li G, Hilgenfeld R, Whitley R, De Clercq E. Therapeutic strategies for COVID-19: progress and lessons learned. Nat Rev Drug Discov. 2023;22(6):449\u201375.","journal-title":"Nat Rev Drug Discov"},{"key":"11007_CR3","doi-asserted-by":"publisher","first-page":"115503","DOI":"10.1016\/j.ejmech.2023.115503","volume":"257","author":"L Yang","year":"2023","unstructured":"Yang L, Wang Z. Bench-to-bedside: innovation of small molecule anti-SARS-CoV-2 drugs in China. Eur J Med Chem. 2023;257:115503.","journal-title":"Eur J Med Chem"},{"key":"11007_CR4","doi-asserted-by":"publisher","first-page":"100794","DOI":"10.1016\/j.drup.2021.100794","volume":"59","author":"S Dro\u017cd\u017cal","year":"2021","unstructured":"Dro\u017cd\u017cal S, Rosik J, Lechowicz K, et al. An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment. Drug Resist Updat. 2021;59:100794.","journal-title":"Drug Resist Updat"},{"key":"11007_CR5","doi-asserted-by":"publisher","first-page":"855496","DOI":"10.3389\/fimmu.2022.855496","volume":"13","author":"L Tian","year":"2022","unstructured":"Tian L, Pang Z, Li M, et al. Molnupiravir and its antiviral activity against COVID-19. Front Immunol. 2022;13:855496.","journal-title":"Front Immunol"},{"issue":"4","key":"11007_CR6","doi-asserted-by":"publisher","first-page":"e28732","DOI":"10.1002\/jmv.28732","volume":"95","author":"F Tian","year":"2023","unstructured":"Tian F, Chen Z, Feng Q. Nirmatrelvir-ritonavir compared with other antiviral drugs for the treatment of COVID-19 patients: A systematic review and meta-analysis. J Med Virol. 2023;95(4):e28732.","journal-title":"J Med Virol"},{"issue":"1","key":"11007_CR7","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1093\/cid\/ciac180","volume":"76","author":"LD Saravolatz","year":"2023","unstructured":"Saravolatz LD, Depcinski S, Sharma M. Molnupiravir and Nirmatrelvir-Ritonavir: oral coronavirus disease 2019 antiviral drugs. Clin Infect Dis. 2023;76(1):165\u201371.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"11007_CR8","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.1038\/s41598-024-53862-y","volume":"14","author":"MP Chen","year":"2024","unstructured":"Chen MP, Jiang DX, Rang JX, Zhuo HB, Zhou ZG. Comparison of Azvudine, Molnupiravir, and Nirmatrelvir\/Ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study. Sci Rep. 2024;14(1):3318.","journal-title":"Sci Rep"},{"key":"11007_CR9","doi-asserted-by":"publisher","first-page":"1143485","DOI":"10.3389\/fmed.2023.1143485","volume":"10","author":"RM Da Silva","year":"2023","unstructured":"Da Silva RM, Gebe Abreu Cabral P, de Souza SB, et al. Serial viral load analysis by DDPCR to evaluate FNC efficacy and safety in the treatment of mild cases of COVID-19. Front Med (Lausanne). 2023;10:1143485.","journal-title":"Front Med (Lausanne)"},{"issue":"11","key":"11007_CR10","doi-asserted-by":"publisher","first-page":"4655","DOI":"10.1016\/j.apsb.2023.07.007","volume":"13","author":"K Zong","year":"2023","unstructured":"Zong K, Zhou H, Li W, Jiang E, Liu Y, Li S. Azvudine reduces the in-hospital mortality of COVID-19 patients: A retrospective cohort study. Acta Pharm Sin B. 2023;13(11):4655\u201360.","journal-title":"Acta Pharm Sin B"},{"issue":"3","key":"11007_CR11","doi-asserted-by":"publisher","first-page":"e342","DOI":"10.1093\/cid\/ciac443","volume":"76","author":"R Najjar-Debbiny","year":"2023","unstructured":"Najjar-Debbiny R, Gronich N, Weber G, et al. Effectiveness of paxlovid in reducing severe coronavirus disease 2019 and mortality in High-Risk patients. Clin Infect Dis. 2023;76(3):e342\u20139.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"11007_CR12","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/S1473-3099(23)00118-4","volume":"23","author":"JA Lewnard","year":"2023","unstructured":"Lewnard JA, McLaughlin JM, Malden D, et al. Effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system. Lancet Infect Dis. 2023;23(7):806\u201315.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"11007_CR13","doi-asserted-by":"publisher","first-page":"e28756","DOI":"10.1002\/jmv.28756","volume":"95","author":"G Deng","year":"2023","unstructured":"Deng G, Li D, Sun Y, et al. Real-world effectiveness of azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19: A retrospective cohort study. J Med Virol. 2023;95(4):e28756.","journal-title":"J Med Virol"},{"issue":"2","key":"11007_CR14","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1016\/j.jinf.2023.05.012","volume":"87","author":"Y Dian","year":"2023","unstructured":"Dian Y, Meng Y, Sun Y, Deng G, Zeng F. Azvudine versus paxlovid for oral treatment of COVID-19 in Chinese patients with pre-existing comorbidities. J Infect. 2023;87(2):e24\u20137.","journal-title":"J Infect"},{"key":"11007_CR15","doi-asserted-by":"publisher","first-page":"102468","DOI":"10.1016\/j.eclinm.2024.102468","volume":"69","author":"S Wang","year":"2024","unstructured":"Wang S, Sun J, Zhang X, et al. Antiviral effectiveness and survival correlation of azvudine and Nirmatrelvir\/ritonavir in elderly severe patients with COVID-19: a retrospective real-world study. EClinicalMedicine. 2024;69:102468.","journal-title":"EClinicalMedicine"},{"issue":"1","key":"11007_CR16","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12879-023-08965-8","volume":"24","author":"X Han","year":"2024","unstructured":"Han X, Gao D, Li C, et al. Real-world effectiveness of nirmatrelvir-ritonavir versus azvudine in hospitalized patients with COVID-19 during the Omicron wave in Beijing: a multicenter retrospective cohort study. BMC Infect Dis. 2024;24(1):57.","journal-title":"BMC Infect Dis"},{"key":"11007_CR17","doi-asserted-by":"publisher","first-page":"1274294","DOI":"10.3389\/fphar.2023.1274294","volume":"14","author":"AH Wei","year":"2023","unstructured":"Wei AH, Zeng L, Wang L, et al. Head-to-head comparison of Azvudine and Nirmatrelvir\/Ritonavir for the hospitalized patients with COVID-19: a real-world retrospective cohort study with propensity score matching. Front Pharmacol. 2023;14:1274294.","journal-title":"Front Pharmacol"},{"issue":"1","key":"11007_CR18","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12879-023-08828-2","volume":"24","author":"P Su","year":"2024","unstructured":"Su P, Yang CX, Wang XG. Azvudine versus paxlovid for oral treatment of COVID-19 in Chinese patients. BMC Infect Dis. 2024;24(1):44.","journal-title":"BMC Infect Dis"},{"key":"11007_CR19","unstructured":"General Office of the National Health Commission. Diagnosis and treatment protocol for COVID-19 in China (trial version 10): National Health Commission of the People\u2019s Republic of China. 2020. http:\/\/en.nhc.gov.cn\/2020-03\/29\/c_78469.htm. Accessed 12 Feb 2023."},{"issue":"4S","key":"11007_CR20","first-page":"S117","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4S):S117\u2013314.","journal-title":"Kidney Int"},{"key":"11007_CR21","doi-asserted-by":"publisher","first-page":"601","DOI":"10.2147\/VHRM.S327661","volume":"17","author":"A Chauin","year":"2021","unstructured":"Chauin A. The main causes and mechanisms of increase in cardiac troponin concentrations other than acute myocardial infarction (Part 1): physical exertion, inflammatory heart disease, pulmonary embolism, renal failure, Sepsis. Vasc Health Risk Manag. 2021;17:601\u201317.","journal-title":"Vasc Health Risk Manag"},{"key":"11007_CR22","first-page":"817","volume":"15","author":"MR McGill","year":"2016","unstructured":"McGill MR. The past and present of serum aminotransferases and the future of liver injury biomarkers. EXCLI J. 2016;15:817\u201328.","journal-title":"EXCLI J"},{"issue":"3","key":"11007_CR23","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res. 2011;46(3):399\u2013424.","journal-title":"Multivar Behav Res"},{"issue":"1","key":"11007_CR24","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s40001-022-00776-y","volume":"27","author":"CC Xu","year":"2022","unstructured":"Xu CC, Xu JL, Wang XF, et al. Prone position reduces the risk of patients with mild or moderate COVID-19 progressing to severe or even critical cases: a retrospective study. Eur J Med Res. 2022;27(1):149.","journal-title":"Eur J Med Res"},{"issue":"1","key":"11007_CR25","doi-asserted-by":"publisher","first-page":"e28443","DOI":"10.1002\/jmv.28443","volume":"95","author":"Y Wang","year":"2023","unstructured":"Wang Y, Zhao D, Liu X, Chen X, Xiao W, Feng L. Early administration of paxlovid reduces the viral elimination time in patients infected with SARS-CoV-2 Omicron variants. J Med Virol. 2023;95(1):e28443.","journal-title":"J Med Virol"},{"issue":"8","key":"11007_CR26","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.3390\/v13081585","volume":"13","author":"M Dejmek","year":"2021","unstructured":"Dejmek M, Konko\u013eov\u00e1 E, Eyer L, et al. Non-Nucleotide RNA-Dependent RNA polymerase inhibitor that blocks SARS-CoV-2 replication. Viruses. 2021;13(8):1585.","journal-title":"Viruses"},{"issue":"1","key":"11007_CR27","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41392-020-00351-z","volume":"5","author":"B Yu","year":"2020","unstructured":"Yu B, Chang J. Azvudine (FNC): a promising clinical candidate for COVID-19 treatment. Signal Transduct Target Ther. 2020;5(1):236.","journal-title":"Signal Transduct Target Ther"},{"issue":"23","key":"11007_CR28","doi-asserted-by":"publisher","first-page":"3349","DOI":"10.1002\/cjoc.202300361","volume":"41","author":"B Yu","year":"2023","unstructured":"Yu B, Chang JA. Nearly 20-Year journey to success of azvudine for antiviral therapy. Chin J Chem. 2023;41(23):3349\u201357.","journal-title":"Chin J Chem"},{"key":"11007_CR29","doi-asserted-by":"publisher","first-page":"114367","DOI":"10.1016\/j.biopha.2023.114367","volume":"162","author":"SMR Hashemian","year":"2023","unstructured":"Hashemian SMR, Sheida A, Taghizadieh M, et al. Paxlovid (Nirmatrelvir\/Ritonavir): A new approach to Covid-19 therapy? Biomed Pharmacother. 2023;162:114367.","journal-title":"Biomed Pharmacother"},{"issue":"7","key":"11007_CR30","doi-asserted-by":"publisher","first-page":"e28947","DOI":"10.1002\/jmv.28947","volume":"95","author":"H Yang","year":"2023","unstructured":"Yang H, Wang Z, Jiang C, et al. Oral azvudine for mild-to-moderate COVID-19 in high risk, nonhospitalized adults: results of a real-world study. J Med Virol. 2023;95(7):e28947.","journal-title":"J Med Virol"},{"issue":"2","key":"11007_CR31","doi-asserted-by":"publisher","first-page":"e28441","DOI":"10.1002\/jmv.28441","volume":"95","author":"B Amani","year":"2023","unstructured":"Amani B, Amani B. Efficacy and safety of Nirmatrelvir\/ritonavir (Paxlovid) for COVID-19: A rapid review and meta-analysis. J Med Virol. 2023;95(2):e28441.","journal-title":"J Med Virol"},{"issue":"4","key":"11007_CR32","doi-asserted-by":"publisher","first-page":"e2551","DOI":"10.1002\/rmv.2551","volume":"34","author":"B Amani","year":"2024","unstructured":"Amani B, Amani B. Azvudine versus paxlovid in COVID-19: A systematic review and meta-analysis. Rev Med Virol. 2024;34(4):e2551.","journal-title":"Rev Med Virol"},{"issue":"9","key":"11007_CR33","doi-asserted-by":"publisher","first-page":"e20153","DOI":"10.1016\/j.heliyon.2023.e20153","volume":"9","author":"Z Chen","year":"2023","unstructured":"Chen Z, Tian F. Efficacy and safety of azvudine in patients with COVID-19: A systematic review and meta-analysis. Heliyon. 2023;9(9):e20153.","journal-title":"Heliyon"},{"issue":"12","key":"11007_CR34","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.3390\/ph15121455","volume":"15","author":"M Li","year":"2022","unstructured":"Li M, Zhang QS, Liu XL, Wang HL, Liu W. Adverse events associated with Nirmatrelvir\/Ritonavir: A pharmacovigilance analysis based on FAERS. Pharmaceuticals. 2022;15(12):1455.","journal-title":"Pharmaceuticals"},{"issue":"15","key":"11007_CR35","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","volume":"386","author":"J Hammond","year":"2022","unstructured":"Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for High-Risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022;386(15):1397\u2013408.","journal-title":"N Engl J Med"},{"issue":"1","key":"11007_CR36","first-page":"36","volume":"21","author":"H Zhu","year":"2023","unstructured":"Zhu H, Yuan YF, Xu Y. Two cases of sinus tachycardia induced by azvudine tablets. Clin Medication J. 2023;21(1):36\u20138. (In Chinese).","journal-title":"Clin Medication J"},{"issue":"12","key":"11007_CR37","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1016\/j.ekir.2022.09.006","volume":"7","author":"C Philipponnet","year":"2022","unstructured":"Philipponnet C, Aniort J, Atenza A, Heng AE, Souweine B. Carfilzomib induced microangiopathy due to accumulation with paxlovid. Kidney Int Rep. 2022;7(12):2746\u20139.","journal-title":"Kidney Int Rep"},{"issue":"11","key":"11007_CR38","first-page":"1027","volume":"26","author":"JJ Jiang","year":"2023","unstructured":"Jiang JJ, Tang YJ, Fan GR, et al. A case analysis of liver injury and bradycardia induced by Nirmatrelvir\/ritonavir tablets combined with Rivaroxaban and Amiodarone. Pract Pharm Clin Rem. 2023;26(11):1027\u201331. (In Chinese).","journal-title":"Pract Pharm Clin Rem"},{"issue":"1","key":"11007_CR39","first-page":"e33831","volume":"15","author":"VM Ganipisetti","year":"2023","unstructured":"Ganipisetti VM, Bollimunta P, Maringanti S. Paxlovid-Induced symptomatic bradycardia and Syncope. Cureus. 2023;15(1):e33831.","journal-title":"Cureus"},{"key":"11007_CR40","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.ijcard.2020.10.028","volume":"324","author":"A Fresse","year":"2021","unstructured":"Fresse A, Viard D, Romani S, et al. Spontaneous reported cardiotoxicity induced by Lopinavir\/Ritonavir in COVID-19. An alleged past-resolved problem. Int J Cardiol. 2021;324:255\u201360.","journal-title":"Int J Cardiol"},{"issue":"11","key":"11007_CR41","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1080\/03007995.2019.1647021","volume":"35","author":"M Kova\u010devi\u0107","year":"2019","unstructured":"Kova\u010devi\u0107 M, Vezmar Kova\u010devi\u0107 S, Radovanovi\u0107 S, Stevanovi\u0107 P, Miljkovi\u0107 B. Adverse drug reactions caused by drug-drug interactions in cardiovascular disease patients: introduction of a simple prediction tool using electronic screening database items. Curr Med Res Opin. 2019;35(11):1873\u201383.","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"11007_CR42","doi-asserted-by":"publisher","first-page":"508","DOI":"10.3390\/v15020508","volume":"15","author":"I Vosko","year":"2023","unstructured":"Vosko I, Zirlik A, Bugger H. Impact of COVID-19 on cardiovascular disease. Viruses. 2023;15(2):508.","journal-title":"Viruses"},{"issue":"2","key":"11007_CR43","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.amjms.2022.01.022","volume":"364","author":"JK Salabei","year":"2022","unstructured":"Salabei JK, Asnake ZT, Ismail ZH, et al. COVID-19 and the cardiovascular system: an update. Am J Med Sci. 2022;364(2):139\u201347.","journal-title":"Am J Med Sci"},{"issue":"7","key":"11007_CR44","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.3390\/v15071598","volume":"15","author":"JE Siegler","year":"2023","unstructured":"Siegler JE, Dasgupta S, Abdalkader M, Penckofer M, Yaghi S, Nguyen TN. Cerebrovascular disease in COVID-19. Viruses. 2023;15(7):1598.","journal-title":"Viruses"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11007-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-11007-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11007-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T21:04:17Z","timestamp":1747256657000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-11007-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11007"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-11007-0","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,14]]},"assertion":[{"value":"2 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This was a retrospective analysis study. The Ethics Committee of The First Affiliated Hospital of Soochow University approved the study. The requirement for informed consent was waived by the Ethics Committee of The First Affiliated Hospital of Soochow University because of the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"701"}}